MC180295 manufacturers
- MC180295
-
- $51.00 / 1mg
-
2024-11-11
- CAS:2237942-08-2
- Min. Order:
- Purity: 99.84%
- Supply Ability: 10g
|
| | MC180295 Basic information |
| Product Name: | MC180295 | | Synonyms: | MC180295 ((REL)-MC180295);MC180295;MC-180295;MC 180295;(rel)-MC180295;Methanone, [4-amino-2-[(1R,2R,4S)-bicyclo[2.2.1]hept-2-ylamino]-5-thiazolyl](2-nitrophenyl)-, rel-;MC180295,MC 180295,Cyclin dependent kinase,MC-180295,CDK,inhibit,Inhibitor | | CAS: | 2237942-08-2 | | MF: | C17H18N4O3S | | MW: | 358.41 | | EINECS: | | | Product Categories: | | | Mol File: | 2237942-08-2.mol |  |
| | MC180295 Chemical Properties |
| Boiling point | 623.8±65.0 °C(Predicted) | | density | 1.462±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 100 mg/mL (279.01 mM) | | form | Solid | | pka | 2.40±0.10(Predicted) | | color | White to off-white |
| | MC180295 Usage And Synthesis |
| Uses | MC180295 can be useful in combination therapy of BET proteolysis targeting chimeric mol. with CDK9 inhibitor against human multiple myeloma cells. | | Biological Activity | MC180295 ((rel)-MC180295) is a novel potent and selective CDK9 inhibitor with IC50 of 5 nM, at least 22-fold selective for CDK9 over other CDKs. | | in vivo | MC180295 has antitumor and immunoallergic activity. | | target | | Target | Value | CDK9-Cyclin T1
(Cell-free assay) | 5 nM | CDK4-Cyclin D
(Cell-free assay) | 112 nM | CDK1-Cyclin B
(Cell-free assay) | 138 nM | | CDK5-P35 < br/> (Cell-free assay) | 159 nM | CDK5-P25
(Cell-free assay) | 186 nM |
|
| | MC180295 Preparation Products And Raw materials |
|